The goal of this pilot clinical trial is to assess the effectiveness of psychodramatic psychotherapy in reducing the psychological distress and/or the skin condition in patients with vitiligo.
The main questions it aims to answer are:
1. Is there any improvement in terms of psychological distress in patients with vitiligo participating in a psychodramatic psychotherapy, compared to a control group?
2. Is there any improvement in terms of skin condition in patients with vitiligo participating in a psychodramatic psychotherapy, compared to a control group? Participants in the experimental group will receive the dermatological drug treatment usually recommended for vitiligo, and in addition they will participate in a 6 months psychodramatic psychotherapy.
Researchers will compare the results of the experimental group with the results of a control group including vitiligo patients who will receive the dermatological pharmacological treatment usually recommended for vitiligo and participate in a 6 months program of self-help activities.

开始日期2023-11-02

申办/合作机构

Università degli Studi di Brescia

[+1]

NCT05988333

/ RecruitingN/AIIT

The Efficacy of Psychoeducational Family Intervention for Individuals With Major Depression: a Randomized Controlled Trial

Major depressive disorder (MDD) is the most common mental disorder. It can be a huge burden not only for the person affected by it, but also for his/her whole family. The goal of this clinical trial is to test the efficacy of a family supportive intervention called psychoeducational family intervention (PFI) compared to a brief informative intervention in families with a member affected by MDD. Families will participate in one of the two interventions for a period of 6 months more or less, and they will be asked to answer some questionnaires about how much MDD impacts on their everyday life and the patient's symptoms, in order to understand whether a more structured intervention such as PFI can be useful for families in order to better deal with this complicated illness.

开始日期2023-09-27

申办/合作机构

University of Campania Luigi Vanvitelli

[+18]

NCT05726500

/ Not yet recruitingN/AIIT

Evaluation of Regional Ventilation Distribution in Patients Affected by Abdominal Sepsis After Emergent Laparotomy

The goal of this clinical trial is to evaluate regional ventilation distribution in patients admitted to the intensive care unit after emergent laparotomy due to abdominal sepsis. The main question it aims to answer is:
• evaluate if patients admitted after an open abdomen strategy have a different regional ventilation distribution compared to patients in which abdomen is closed at the end of the procedure
Participants will undergo non-invasive monitoring (esophageal pressure and electrical impedance tomography) and an blood gas analysis samples.
Researchers will compare open abdomen group and closed abdomen group to see if the ventilation distribution pattern is different.

开始日期2023-02-15

申办/合作机构

Università degli Studi di Brescia

[+1]

100 项与 Università degli Studi di Brescia 相关的临床结果

登录后查看更多信息

0 项与 Università degli Studi di Brescia 相关的专利（医药）

登录后查看更多信息

14,967

项与 Università degli Studi di Brescia 相关的文献（医药）

2025-12-31·Italian Journal of Animal Science

Effects of dietary supplementation with olive cake enriched in polyphenols on growth, rumen fermentation, and metabolic status of finishing Limousine bulls

作者: Llobat, L. ; Amato, A. ; Chiofalo, V. ; Cavallo, C. ; Ferronato, G. ; Liotta, L. ; Lopreiato, V. ; Trevisi, E.

HIGHLIGHTSThe integration of olive cake in ruminants′ diet can represent a path to reduce environmental impact and cost-associated disposal.Finishing Limousine bulls supplemented with olive cake showed higher rumen propionate and heptanoate and lower acetate, isobutyrate, and isovaleriate content than control bulls.The supplementation of olive cake influenced metabolic, liver, and antioxidant markers in finishing Limousine bulls, suggesting it could have not well understood effects on their health status.

2025-03-01·JOURNAL OF NEUROPHYSIOLOGY

Changes in thoracic erector spinae regional activation during postural adjustments and functional reaching tasks after spinal cord injury

Article

作者: Martinez-Valdes, Eduardo ; Alexander, Emma ; Falla, Deborah ; Chowdhury, Joy Roy ; Cabral, Hélio V. ; Strutton, Paul H. ; Chiou, Shin-Yi ; van Helden, Joeri F. L.

We demonstrate that individuals with chronic incomplete spinal cord injury (SCI) recruit lower part of the thoracic erector spinae (ES) for postural control of the trunk. We also show that activation was restricted in a smaller part of the ES, and the discrete control of the ES was lost during functional reaching movements in individuals with SCI. Our study provides evidence of alterations in neural control between vertebral levels in individuals with SCI.

2025-03-01·INTERNATIONAL JOURNAL OF LEGAL MEDICINE

Exploring radiomic features of lateral cerebral ventricles in postmortem CT for postmortem interval estimation

Article

作者: Pascali, Vincenzo L ; Boldrini, Luca ; Bergamin, Eva ; Guerreri, Michele ; Gatta, Roberto ; De-Giorgio, Fabio ; Sala, Evis ; De Vita, Vittorio ; Mancino, Matteo

The aim of this study is to investigate the potential of radiomic features extracted from postmortem computed tomography (PMCT) scans of the lateral cerebral ventricles (LCVs) to provide information on the time since death, or postmortem interval (PMI), a critical aspect of forensic medicine. Periodic PMCT scans, referred to as "sequential scans", were obtained from twelve corpses with known times of death, ranging from 5.5 to 273 h postmortem. Radiomics features were then extracted from the LCVs, and a mixed-effect model, specifically designed for sequential data, was employed to assess the association between feature values and PMI. Four model variants were fitted to the data to identify the best functional form to explain the relationship between the variables. Significant associations were observed for features, the most significant being the median Hounsfield Units (HU) within the LCVs (p < 9.47 × 10⁻⁹), LCVs surface area (p < 4.69 × 10⁻⁶), L-major axis (p < 2.17 × 10⁻⁵), L-minor axis (p < 1.30 × 10⁻⁴), and HU entropy (p < 4.16 × 10⁻⁴). Our findings align with previous studies, supporting a logarithmic model for PMI-related changes in LCV volume and mean HU intensity value. This study highlights the potential of PMCT-based radiomics as source of complementary information that could be integrated into existing methods for PMI estimation. Our results support the application of a quantitative imaging approach in forensic investigations.

项与 Università degli Studi di Brescia 相关的新闻（医药）

2022-01-19

·NS Medical Devices

Diadem gets FDA breakthrough status for blood test to detect Alzheimer’s

AlzoSure is the first prognostic blood test to predict the likeliness of Alzheimer's disease progression, up to six years in advance Diadem’s AlzoSure is a blood test that predicts Alzheimer’s disease. Diadem has received the US Food and Drug Administration (FDA) Breakthrough Device Designation for the AlzoSure Predict blood test to predict the Alzheimer’s disease (AD). According to the company, AlzoSure Predict is a blood-based biomarker prognostic assay intended for the early prediction of AD. The test identifies the chances of Alzheimer’s disease progression in cognitive impairment patients, aged 50 years and above, up to six years prior to the onset of definitive symptoms. Diadem CEO Paul Kinnon said: “Obtaining this FDA Breakthrough Device designation reinforces our view that AlzoSure Predict is a potential game changer for the early identification and management of Alzheimer’s disease, which afflicts millions of patients and their families worldwide. “We see the Breakthrough Device designation as an important step in supporting the future commercialization of AlzoSure Predict in the US and globally, and we look forward to working closely with the FDA to complete our clinical studies and expedite the regulatory review process.” Diadem’s regulatory application with the US FDA was based on positive data from a study of AlzoSure Predict in 482 cognitive impairment patients, aged 50 years or older. The study showed that AlzoSure Predict is capable of identifying the likeliness of disease progression to full-fledged AD, up to six years prior to the symptomatic illness. The second phase of this study, which includes biobank data on more than 1,000 additional patients from the US and Europe, is anticipated to be completed in the coming months. Alzheimer’s disease is the most common form of dementia that accounts for 60-70% of cases, with no disease modifying treatments, and limited therapies to treat symptoms. Diadem, a spin-off from the University of Brescia, Italy, is developing AlzoSure Predict as a simple, non-invasive plasma-based biomarker assay to predict the progression of AD. The company’s leverages its patented antibody technology to target U-p53AZ, a conformational variant of the p53 protein, and its sequences.

抗体

100 项与 Università degli Studi di Brescia 相关的药物交易

登录后查看更多信息

100 项与 Università degli Studi di Brescia 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

或

查看完整样例数据

管线布局

2025年04月04日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

药物发现

临床前

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

UniPR-1331 ( EphA2 )	实体瘤更多	临床前
Hepcidin Inhibition(University of Brescia) ( Hepc )	贫血更多	临床前
CB2 modulators(Università degli Studi di Brescia) ( CB2 )	炎症更多	药物发现